menu
    • menu
    [{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"||DGAT","graph1":"Neurology","graph2":"Preclinical","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Aker BioMarine \/ Aker BioMarine"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Aker BioMarine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Carbohydrate","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ Aker BioMarine","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ Aker BioMarine"}]

    Find Clinical Drug Pipeline Developments & Deals by Aker BioMarine

    Menu

    Aker BioMarine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aker BioMarine

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Krill,Venelex,Krill Oil,Carbohydrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : University of Glasgow

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigating the Effects of Krill Oil and Krill Protein on Post-exercise Muscle Protein Metabolism

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 17, 2023

                            Lead Product(s) : Krill,Venelex,Krill Oil,Carbohydrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : University of Glasgow

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aker BioMarine

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl,DHA

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Universite de Sherbrooke Department of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aker BioMarine Enters Into Research Collaboration for Alzheimer’s

                            Details : Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.

                            Product Name : Lysoveta

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 15, 2021

                            Lead Product(s) : Icosapent Ethyl,DHA

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Universite de Sherbrooke Department of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aker BioMarine

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKR-963,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 27, 2010

                            Lead Product(s) : AKR-963,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth